This is SurGenTech’s inaugural implant in the sacroiliac family of products, according to a June 8 press release.
The TiLink has distinct features from other products on the market, including a design that allows for superior compression across the joint. It is also equipped with SurGenTec’s proprietary Nanotex surface technology and boasts a helical self-harvesting channel to capture the patient’s own bone and encourage healing, according to the release.
The sacroiliac joint fusion market is projected to witness substantial growth in the coming years as the population ages and the demand for minimally invasive procedures increases.
“We are thrilled to announce the FDA clearance of our first treatment option in our sacroiliac family of products,” Travis Greenhalgh, CEO of SurGenTec, said in the release. “With its unique properties and ability to adapt to diverse patient needs, TiLink-L is set to offer physicians the ability to stabilize the sacroiliac joint in a variety of approaches. Whether in an outpatient or hospital setting, we believe this device is poised to make a significant difference in patient care.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
